Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer

October 17th 2025

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

October 16th 2025

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

Dr Visco on the Design of the FIL_V-RBAC Trial of RBAC Plus Venetoclax in High-Risk MCL

October 16th 2025

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

October 16th 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Study Shows ChatGPT Struggles With Patient-Specific Queries, Novel Therapies in Hematologic Malignancies

October 16th 2025

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

Dr Tarantino on the Role of Genomic Testing in HER2+ Breast Cancer

October 16th 2025

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Dr Randall on the Diagnostic Accuracy and Cost Effectiveness of MRI vs Ultrasound in STS

October 16th 2025

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

October 15th 2025

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Dr Le on the Efficacy of Firmonertinib for the Treatment of EGFR PACC–Mutated NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma

October 15th 2025

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

October 15th 2025

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.

Dr Lee on the Role of IMRT in Locally Advanced NSCLC Management

October 14th 2025

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

PEACE-3 Data Add to Expanding Evidence Clarifying Radium-223 Use in mCRPC

October 14th 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

NEXT PAGE
PREVIOUS PAGE